Skip to main content

Table 1 Baseline characteristics of all study patients (n = 45)

From: Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study

 AllQ1Q2Q3Q4P
n = 45n = 11n = 12n = 11n = 11
Urinary A-megalin (pmol/g Cr)
 Mean ± SD or [Median]87.9 ± 46.6[36.1][76.0][95.8][150.4] 
 Range1.6–203.61.6–52.968.3–79.879.9–118.9119.8–203.6 
Age, years
 Mean ± SD64.6 ± 8.262.1 ± 8.965.8 ± 4.965.5 ± 8.464.8 ± 10.30.702
Sex, n (%)     0.399
 Female9 (20.0)3 (27.3)4 (33.3)1 (9.1)1 (9.1) 
 Male36 (80.0)8 (72.7)8 (66.7)10 (90.9)10 (90.9) 
Body height, cm
 Mean ± SD163.9 ± 7.2165.0 ± 6.9161.3 ± 6.0165.2 ± 7.0164.5 ± 8.90.528
Body weight, kg
 Mean ± SD57.7 ± 10.160.2 ± 10.259.9 ± 12.854.3 ± 10.656.0 ± 4.90.437
Smoking status, n (%)     0.527
 Current/former40 (88.9)10 (90.9)10 (83.3)11 (100)9 (81.8) 
 Never5 (11.1)1 (9.1)2 (16.7)0 (0.0)2 (18.2) 
Baseline therapies, n (%)
 RAS inhibitors10 (22.2)3 (27.3)2 (16.7)4 (36.3)1 (9.1)0.457
 NSAIDs22 (48.9)5 (45.5)5 (45.5)4 (36.3)8 (72.7)0.340
Baseline comorbidity, n (%)
 Hypertension20 (44.0)3 (27.3)9 (75.0)5 (45.5)3 (27.3)0.066
 Diabetes9 (20.0)1 (9.1)2 (16.7)3 (27.3)3 (27.3)0.675
Initial eGFR (mL/min/1.73 m2)    0.372
 Mean ± SD89.7 ± 15.983.7 ± 16.287.9 ± 17.192.9 ± 17.694.6 ± 11.9 
9024 (53.3)4 (36.4)8 (66.7)6 (54.5)6 (54.5) 
 60–8920 (44.4)7 (63.6)3 (25.0)5 (45.5)5 (45.5) 
591 (2.2)0 (0.0)1 (8.3)0 (0.0)0 (0.0) 
Cisplatin dose (mg/m2)
 Mean ± SD76.0 ± 5.073.2 ± 6.877.5 ± 2.675.9 ± 5.877.3 ± 2.60.143
Type of malignancy, n (%)
 NSCLC33     
 SCLC10     
 MPM2     
  1. eGFR, estimate glomerular filtration rate; Cr, creatinine; MPM, malignant pleural mesothelioma; NSAID, non-steroidal anti-inflammatory drug; NSCLC, non-small cell lung cancer; RAS, renin-angiotensin-aldosterone system; SCLC, small cell lung cancer; SD, standard deviation